Trillium Therapeutics Expands Clinical Trial

Trillium Therapeutics (NASDAQ:TRIL; TSX:TRIL) will expand its current dosing clinical trial of TTI-621.
As quoted in the press release:

Changes to the trial include:

• An additional cohort of patients with Hodgkin lymphoma treated with a combination of TTI-621 and the PD-1 checkpoint inhibitor nivolumab
• Two additional cohorts of patients with T- and B-cell acute lymphoblastic leukemia and small cell lung cancer treated with TTI-621 monotherapy
• Cautious exploration of dose-intensification, building upon the observation of good overall tolerability associated with attenuated thrombocytopenia over successive weekly doses of TTI-621
• Increasing the size of cohorts exhibiting early evidence of clinical benefit

“Having observed meaningful objective responses among multiple treatment-refractory cancer patients, we are now expanding the trial’s scope with additional focused enrollment to extend these preliminary observations and to seek promising new signals of activity – both with TTI-621 monotherapy, with rituximab, and in a novel combination with T-cell checkpoint inhibition,” said Trillium’s Chief Medical Officer, Dr. Eric Sievers. “With emerging data linking CD47 blockade with T cell activation, we are excited to pursue the combination of TTI-621 and nivolumab in an attempt to optimally engage both the innate and adaptive arms of the immune system to generate a robust and enduring anti-tumor response.”

Click here to read the full press release.

Source: www.marketwired.com